<DOC>
	<DOCNO>NCT03030391</DOCNO>
	<brief_summary>Background : The new drug 18F-PF-06445974 little radioactivity . This see positron emission tomography ( PET ) scan . The drug help researcher see protein , PDE4B , brain . Looking PDE4B live brain might show involved psychiatric neurological disorder . One part study look study drug distribute brain . Another part study brain measure vary . Objectives : To measure protein PDE4B brain . To test new radioactive chemical , 18F-PF-06445974 , distribute body . Eligibility : Healthy adult age 18 old Design : Participants 1-3 visit year . Each 2-5 hour . Women pregnancy test time .</brief_summary>
	<brief_title>Novel Positron Emission Tomography ( PET ) Radiotracer Image Phosphodiesterase-4B ( PDE4B )</brief_title>
	<detailed_description>Objective : Phosphodiesterase type 4 ( PDE4 ) terminate signal transduction guanine nucleotidebinding protein ( G-protein ) -coupled receptor metabolize second messenger 3 &lt; =,5 &lt; =- cyclic adenosine monophosphate ( cAMP ) . PDE4 selective cAMP cyclic guanosine monophosphate . PDE4 four isozymes A , B , C , D basic study indicate type B ( PDE4B ) play key role cognitive function neuroinflammation . Thus , PDE4B inhibitor would expect improve cognitive function anti-inflammatory effect . Pfizer develop new PET ligand , 18F-PF-06445974 , selectively image PDE4B ; ligand show promising result non-human primate . This protocol cover four phase : 1 . Phase 1 : whole body image one subject low injection activity 2 mCi confirm organ prominently high uptake 18F-PF-06445974 ; 2 . Phase 2 : kinetic brain image 5 mCi injection quantify PDE4B brain relative concurrent measurement parent radioligand arterial plasma ; 3 . Phase 3 : 18F-PF-06445974 successful Phase 2 first couple subject , estimate radiation-absorbed dos perform whole body image 5 mCi injection ; 4 . Phase 4 : test-retest analysis brain bind relative concurrent measurement parent radioligand arterial plasma ( 5 mCi per scan ) . Study Population : Healthy adult female male volunteer ( n=22 , age 18 older ) undergo brain imaging . An additional eight healthy volunteer undergo whole body dosimetry analysis , total 30 healthy volunteer . Design : For quantification 18F-PF-06445974 , 22 healthy control undergo brain PET image use 18F-PF-06445974 arterial line . Some test-retest scan . Eight additional subject whole body PET scan dosimetry . For dosimetry , arterial line use . Outcome Measures : To assess quantitation PDE4B 18F-PF-06445974 , primarily use two outcome measure , namely identifiability time stability distribution volume ( VT ) calculate compartmental modeling . In test-retest study , calculate retest variability . We assess whole-body biodistribution dosimetry 18F-PF-06445974 calculating dos organ effective dose body .</detailed_description>
	<criteria>INCLUSION CRITERIA : Age 18 older . Able give write informed consent . Medically psychiatrically healthy . Enrolled 01M0254 The Evaluation Participants Mood Anxiety Disorders Healthy Volunteers ( PI : Dr. Carlos Zarate ) . EXCLUSION CRITERIA : Any current Axis I diagnosis . Clinically significant laboratory abnormality Positive HIV test . Unable MRI scan . History neurologic illness injury potential affect study data interpretation . Recent exposure radiation relate research ( i.e . PET research ) , combine study , would allowable limit . Inability lie flat camera bed least two hour . Pregnancy breastfeed . Current substance use disorder base DSM5 . Current use psychiatric medication . NIMH employees/staff immediate family member exclude study per NIMH policy . Exclusion criterion dosimetry subject report , exception MRI contraindication , MRI perform subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 13, 2017</verification_date>
	<keyword>Camp</keyword>
	<keyword>Radiation Absorbed Dose</keyword>
	<keyword>Compartmental Analysis</keyword>
</DOC>